These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31598491)

  • 1. Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
    Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
    Front Oncol; 2019; 9():967. PubMed ID: 31598491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
    Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
    Front Oncol; 2019; 9():707. PubMed ID: 31448227
    [No Abstract]   [Full Text] [Related]  

  • 3. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
    Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Dieci MV; Prat A; Tagliafico E; Paré L; Ficarra G; Bisagni G; Piacentini F; Generali DG; Conte P; Guarneri V
    Ann Oncol; 2016 Oct; 27(10):1867-73. PubMed ID: 27484801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
    Swain SM; Tang G; Lucas PC; Robidoux A; Goerlitz D; Harris BT; Bandos H; Geyer CE; Rastogi P; Mamounas EP; Wolmark N
    Breast Cancer Res Treat; 2019 Nov; 178(2):389-399. PubMed ID: 31428908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of the intrinsic molecular subtypes of breast cancer.
    Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
    Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?
    Wu J; Kong R; Tian S; Li H; Wu K; Kong L
    Chin J Cancer Res; 2019 Dec; 31(6):878-891. PubMed ID: 31949390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer.
    Zhao Y; Dong X; Li R; Ma X; Song J; Li Y; Zhang D
    Onco Targets Ther; 2015; 8():1511-21. PubMed ID: 26150728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Ohara AM; Naoi Y; Shimazu K; Kagara N; Shimoda M; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Feb; 173(3):533-543. PubMed ID: 30361874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
    Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
    Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
    Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
    Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.